There is news on the reimbursement front for pharmacogenomics. Recently, a proposed local coverage determination (LCD) was put forth by a group of Medicare Administrative Contractors (MACs) following a meeting of subject matter experts and Contractor Advisory Committee (CAC) members. While this is not national nor 100% comprehensive, this could set an important precedent in the reimbursement front for pharmacogenomic testing.
The open comment period starts 10/7/19 and is open until 11/21/19. Feel free to share your thoughts here.